Compare S&P Global Inc (SPGI) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
S&P Global Inc vs Travere Therapeutics Inc. Common Stock — how do they compare? S&P Global Inc trades at $406.53 (market cap $120.87B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: S&P Global Inc is far larger — about 24.8× Travere Therapeutics Inc. Common Stock's market cap, and S&P Global Inc pays a 0.95% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold S&P Global Inc for 124 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| SPGI | TVTX | |
|---|---|---|
Market Cap | $120.87B | $4.88B |
Volume | 1,391,754 | 1,668,577 |
Sector | Financials | Health |
52-Week High | $517.92 | $67.52 |
52-Week Low | $370.42 | $26.79 |
Typical Hold Time | 124 Days | 0 Days |
Enterprise Value | $132.35B | $5.01B |
Dividend Yield | 0.95% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
S&P Global (SPGI) trades at $408.57, down 0.88% on the day, with a bullish technical signal despite mixed moving averages. The company reported strong fundamentals with Q1 and Q2 2026 earnings beats, revenue growth to $15.34B in 2025, and robust profitability margins. Recent news highlights expansion into digital asset risk assessment and AI-driven growth initiatives.
Outlook remains positive with an 85.7% analyst buy rating and a $509.50 consensus price target, implying significant upside. Key risks include execution of acquisitions and macroeconomic sensitivity, but the firm's entrenched market position and cash flow stability support a favorable investment case for long-term holders.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About S&P Global Inc
S&P Global provides data and benchmarks to capital and commodity market participants. In 2021 and excluding IHS Markit, S&P Ratings was over 45% of the firm's revenue and over 55% of the firm's operating income. S&P Ratings is the largest credit rating agency in the world. The firm's other segments include Market Intelligence, Indices, and Platts. Market Intelligence provides desktop tools and other data solutions to investment banks, corporations, and other entities. Indices provides benchmarks for financial markets and is monetized through subscriptions, asset-based fees, and transaction-based royalties. Platts provides benchmarks to commodity markets, principally petroleum.
Read more on SPGI →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
